Conmed (CNMD) Tops Q2 EPS by 1c; Raises Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
CONMED (CNMD) PT Raised to $83 at Needham & Company
August 2, 2018 6:43 AM EDTNeedham & Company raised its price target on CONMED (NASDAQ: CNMD) to $83.00 (from $73.00) while maintaining a Buy rating.
Analyst Mike Matson commented, "CNMD's 2Q18 revenue and EPS beat consensus and management raised its 2018 revenue and maintained its EPS guidance. Revenue growth improved... More
